ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

INV-347

A development code.

Its studies are mostly in Obesity, led by Novo Nordisk.

Furthest: phase 1, since Jul 28, 20251 company-led study, 1 open or runningNext primary completion: Sep 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk11 open or runningphase 1since Jul 28, 2025Jul 28, 2025Sep 15, 2027phase 1 · NCT07153172

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2025First study: phase 1 study in ObesityFirst studyNCT07153172 · 91 planned · Canada

Ahead

  1. Sep 15, 2027Primary completion: phase 1 study in ObesityNCT07153172

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07153172Obesity · Canada1RecruitingSep 15, 202791

How it is read

Names in the registry

  • “INV-347”, 1 entry

Codes read as this program: INV347.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.